Table 2.
Evolution of symptoms at six months from Omicron SARS-CoV-2 infection in 294 COVID-19 patients.
| Acute phase |
6-Month follow-up |
|||||
|---|---|---|---|---|---|---|
| n | % | (95 % CI)a | n | % | (95 % CI) | |
| Chemosensory impairment (SNOT-22 ≥ 1) | ||||||
| Yes | 101 | 34.4 | (28.9–40.1) | 4 | 1.4 | (0.4–3.4) |
| No | 193 | 65.6 | (59.9–71.1) | 290 | 98.6 | (96.6–99.6) |
| Type of chemosensory impairment | ||||||
| Smell & taste | 67 | 22.8 | (18.1–28.0) | 3 | 1.0 | (0.2–3.0) |
| Only smell | 16 | 5.4 | (3.1–8.7) | 1 | 0.3 | (0.0–1.9) |
| Only taste | 18 | 6.1 | (3.7–9.5) | 0 | 0.0 | (0.0–1.2) |
| Severity of alteration of sense of smell or taste (SNOT-22) | ||||||
| 0 = None | 193 | 65.6 | (59.9–71.1) | 290 | 98.6 | (96.6–99.6) |
| 1 = Very mild | 20 | 6.8 | (4.2–10.3) | 0 | 0.0 | (0.0–1.2) |
| 2 = Mild/slight | 25 | 8.5 | (5.6–12.3) | 2 | 0.7 | (0.1–2.4) |
| 3 = Moderate | 25 | 8.5 | (5.6–12.3) | 1 | 0.3 | (0.0–1.9) |
| 4 = Severe | 15 | 5.1 | (2.9–8.3) | 1 | 0.3 | (0.0–1.9) |
| 5 = As bad as it can be | 16 | 5.4 | (3.1–8.7) | 0 | 0.0 | (0.0–1.2) |
Abbreviations: SNOT-22: Sino Nasal Outcome Test 22.